RoMEA Blood Screening Market to 2032
Overview
The RoMEA Blood Screening Market is expected to reach a 50.07 USD Million by 2032 and is projected to grow at a CAGR of 11.00% from 2025 to 2032.
Revenue, 2024 (USD Million)
26.24
Forecast, 2032 (USD Million)
50.07
CAGR, 2024 - 2032
11.00%
Report Coverage
RoMEA
RoMEA Blood Screening Market 2018-2032 USD Million
RoMEA Blood Screening Market, Key Findings (2025-2032)
Market Growth and Projections:
- Market Size (2024): 26.24 USD Million
- Projected Market Size (2032): 50.07 USD Million
- CAGR (2025-2032): 11.00%
Key Findings of RoMEA Blood Screening Market
- The RoMEA Blood Screening Market was valued at 26.24 USD Million in 2024.
- The RoMEA Blood Screening Market is likely to grow at a CAGR of 11.00% during the forecast period of 2024 to 2032.
- In 2024, the Largest segment Reagents & Kits in Products & Services Segment accounted for the largest share of the market with a revenue of 13.89 USD Million
- The fastest growing segment Next-Generation Sequencing (NGS) in Technology Segment grew Fastest with a CAGR of 11.85% during the forecast period from 2024 to 2032.
RoMEA Blood Screening Market Scope
RoMEA Blood Screening Market Segmentation & Scope
Products & Services
- Software & Services
- Instruments
- Reagents & Kits
Technology
- Others
- Western Blot Assay
- Nucleic Acid Test
- Next-Generation Sequencing (NGS)
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Rapid Tests
Disease Type
- Others
- HIV/AIDS
- Respiratory Diseases
- Infectious Diseases
- Cholesterol
- Cold & Flu
- Diabetes Mellitus
- Oncology
End User
- Ambulatory Surgical Centers
- Clinics
- Hospitals
- Blood Bank
- Diagnostic Centers
RoMEA Blood Screening Market Data Coverage Insights
| Study Period | 2024-2032 |
| Base Year | 2022 |
| Unit | Revenue in USD Million |
| Market Value in 2024 | 26.24 USD Million |
| Market Value in 2032 | 50.07 USD Million |
| CAGR (2025-2032) | 11.00% |
| Historic Data | 2016-2023 |
| Market Segments Covered | Products & Services,Technology,Disease Type,End User |
Regional Insights:
-
Leading Market (2024-2032): RoMEA, leading in terms of revenue 26.24 USD Million in 2024
- Key Country: RoMEA, leading in terms of revenue with value of 26.24 USD Million in 2024.
Segments and Scope
-
RoMEA Blood Screening Market to 2032, By Products & Services
- Reagents & Kits is the largest segment in RoMEA Blood Screening Market to 2032 with a revenue of 13.89 USD Million in the year 2024.
- Instruments is the Fastest growing segment in RoMEA Blood Screening Market to 2032 with a Growth rate of 10.78 % in forecast period 2025-2032.
-
RoMEA Blood Screening Market to 2032, By Technology
- Enzyme-Linked Immunosorbent Assay (ELISA) is the largest segment in RoMEA Blood Screening Market to 2032 with a revenue of 10.96 USD Million in the year 2024.
- Next-Generation Sequencing (NGS) is the Fastest growing segment in RoMEA Blood Screening Market to 2032 with a Growth rate of 11.40 % in forecast period 2025-2032.
-
RoMEA Blood Screening Market to 2032, By Disease Type
- Oncology is the largest segment in RoMEA Blood Screening Market to 2032 with a revenue of 10.79 USD Million in the year 2024.
- Diabetes Mellitus is the Fastest growing segment in RoMEA Blood Screening Market to 2032 with a Growth rate of 11.64 % in forecast period 2025-2032.
-
RoMEA Blood Screening Market to 2032, By End User
- Diagnostic Centers is the largest segment in RoMEA Blood Screening Market to 2032 with a revenue of 10.12 USD Million in the year 2024.
- Diagnostic Centers is the Fastest growing segment in RoMEA Blood Screening Market to 2032 with a Growth rate of 11.77 % in forecast period 2025-2032.
RoMEA Blood Screening Market Company Share Analysis
| Company Name |
|
||
| INNOVUS PHARMACEUTICALS, INC. | |||
| Pfizer Inc. | |||
| Bayer AG | |||
| Cipla Inc. | |||
| GSK plc. | |||
RoMEA Blood Screening Market Geographical Sales Distribution, 2018-2032 USD Million
RoMEA Blood Screening Market Company Profiling
Industry Related Reports
Frequently Asked Questions
The RoMEA Blood Screening Market is segmented based on Segmentation Products & Services,Technology,Disease Type,End User.
RoMEA Blood Screening Market was valued at USD 26.24(Revenue in USD Million) in 2022.
RoMEA Blood Screening Market is projected to grow at a CAGR of 11.00% during the forecast period of 2024 to 2032.
The Reagents & Kits segment is expected to dominate the RoMEA Blood Screening Market, holding a largest market share of 13.89 USD Million in 2024
RoMEA Blood Screening Market Scope
RoMEA Blood Screening Market Segmentation & Scope
Products & Services
- Software & Services
- Instruments
- Reagents & Kits
Technology
- Others
- Western Blot Assay
- Nucleic Acid Test
- Next-Generation Sequencing (NGS)
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Rapid Tests
Disease Type
- Others
- HIV/AIDS
- Respiratory Diseases
- Infectious Diseases
- Cholesterol
- Cold & Flu
- Diabetes Mellitus
- Oncology
End User
- Ambulatory Surgical Centers
- Clinics
- Hospitals
- Blood Bank
- Diagnostic Centers
Frequently Asked Questions
The RoMEA Blood Screening Market is segmented based on Segmentation Products & Services,Technology,Disease Type,End User.
RoMEA Blood Screening Market was valued at USD 26.24(Revenue in USD Million) in 2022.
RoMEA Blood Screening Market is projected to grow at a CAGR of 11.00% during the forecast period of 2024 to 2032.
The estimated market value of the RoMEA Blood Screening Market for final year is USD 50.07 (USD Million).
RoMEA Blood Screening Market Company Profiling
Frequently Asked Questions
The RoMEA Blood Screening Market is segmented based on Segmentation Products & Services,Technology,Disease Type,End User.
RoMEA Blood Screening Market was valued at USD 26.24(Revenue in USD Million) in 2022.
RoMEA Blood Screening Market is projected to grow at a CAGR of 11.00% during the forecast period of 2024 to 2032.
The estimated market value of the RoMEA Blood Screening Market for final year is USD 50.07 (USD Million).
HAVE A QUESTION?
Get expert advice on the right strategy for your business at no cost. We also offer customized subscription plans and affordable discounts for startups and universities.